MedTrace Logo

UCLA-Amity Parolee Health Promotion Study

NCT01844414 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2015-05-28

No results posted yet for this study

Summary

The purpose of this study is to conduct a prospective, three-group study that randomly assigns 700 parolees, in a community residential drug treatment program, to enter one of three groups: 1) a PCPC (Parolee Comprehensive Care + Phone Coaching Program), which includes nurse case management and specialized hepatitis education sessions and the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone); 2) a Parolee Brief Hepatitis Education + HBV vaccination + Phone Coaching (PBCP) Program, which includes brief hepatitis/HIV education, HAV/HBV vaccination and coach-facilitated mentoring; or 3) a Usual Care (UC) control program, which includes brief general health information, one-on-one coaching and the HAV/HBV vaccine.

Conditions

Interventions

BEHAVIORAL

Parolee Comprehensive Care + Phone Coach

A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).

BEHAVIORAL

Parolee Brief HBV Program + Phone Coach

A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.

BEHAVIORAL

Usual Care Group

Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine

Sponsors & Collaborators

Principal Investigators

  • Adeline Nyamathi, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-01-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01844414 on ClinicalTrials.gov